Patents by Inventor Bradley Lunde
Bradley Lunde has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11034737Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.Type: GrantFiled: July 8, 2019Date of Patent: June 15, 2021Assignee: Pieris Pharmaceuticals GmbHInventors: Gabriele Matschiner, Christine Rothe, Alexander Wiedenmann, Rachida Siham Bel Aiba, Marlon Hinner, Andrea Allersdorfer, Bradley Lunde, Kazufumi Kubota, Mitsuhiro Makino, Sakiko Takahashi, Ryuji Hashimoto, Tohru Takahashi, Mamoru Otoyo
-
Patent number: 10947284Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.Type: GrantFiled: April 24, 2019Date of Patent: March 16, 2021Assignee: Pieris Pharmaceuticals GmbHInventors: Carsten Corvey, Heike Stump, Jochen Kruip, Christian Lange, Ingo Focken, Dorothea Rat, Thomas Stuedemann, Hans-Falk Rasser, Juergen Schaefer, Bernard Calandra, Astrid Rey, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Patent number: 10927154Abstract: The disclosure provides a multi-specific polypeptide with a first moiety specific for a tumor-associated antigen on tumor cell surface and a second moiety specific for an immune checkpoint protein, which multi-specific polypeptide can be useful for biasing a T-cell-mediated response to a tumor micro-environment. For example, the polypeptide may contain: a) a first binding domain, for example, a full-length antibody or an antigen-binding domain of an antibody, specifically recognizing a tumor-associated antigen on tumor cell surface, and b) a second binding domain, such as a lipocalin mutein, capable of stimulating T-cell proliferation e.g., by inhibiting a protein receptor that down-regulates the immune system. The first binding domain may be genetically linked (i.e., peptide bond at its N- or C-terminus) to the second binding domain. The multispecific polypeptide also may contain a third or yet additional specific binding moieties, any of which can specifically bind a distinct immune checkpoint protein.Type: GrantFiled: January 12, 2015Date of Patent: February 23, 2021Assignee: Pieris Pharmaceuticals GmbHInventors: Shane Olwill, Alexander Wiedenmann, Andrea Allersdorfer, Rachida Bel Aiba, Gabriele Matschiner, Bradley Lunde
-
Publication number: 20190382455Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.Type: ApplicationFiled: April 24, 2019Publication date: December 19, 2019Inventors: Carsten Corvey, Heike Stump, Jochen Kruip, Christian Lange, Ingo Focken, Dorothea Rat, Thomas Stuedemann, Hans-Falk Rasser, Juergen Schaefer, Bernard Calandra, Astrid Rey, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Publication number: 20190338002Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules.Type: ApplicationFiled: July 8, 2019Publication date: November 7, 2019Inventors: Gabriele Matschiner, Christine Rothe, Alexander Wiedenmann, Rachida Siham Bel Aiba, Marlon Hinner, Andrea Allersdorfer, Bradley Lunde, Kazufumi Kubota, Mitsuhiro Makino, Sakiko Takahashi, Ryuji Hashimoto, Tohru Takahashi, Mamoru Otoyo
-
Patent number: 10400016Abstract: The present disclosure provides hNGAL muteins that bind CGRP and can be used in various application including pharmaceutical applications, for example, migraine. The present disclosure also concerns methods of making one or more muteins described herein as well as compositions and combinations comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions and combinations comprising one or more of such muteins.Type: GrantFiled: December 7, 2016Date of Patent: September 3, 2019Assignee: PIERIS PHARMACEUTICALS GMBHInventors: Gabriele Matschiner, Christine Rothe, Alexander Wiedenmann, Rachida Siham Bel Aiba, Marlon Hinner, Andrea Allersdorfer, Bradley Lunde, Kazufumi Kubota, Mitsuhiro Makino, Sakiko Takahashi, Ryuji Hashimoto, Tohru Takahashi, Mamoru Otoyo
-
Patent number: 10329334Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: GrantFiled: November 16, 2017Date of Patent: June 25, 2019Assignee: SANOFIInventors: Carsten Corvey, Heike Stump, Jochen Kruip, Bernhard Calandra, Astrid Rey, Nathalie Karst, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Patent number: 10316071Abstract: The present invention relates to fusion molecules that have binding specificity for pyoverdine type I, II and III and pyochelin and can be used in various applications, including diagnostic and/or therapeutic applications, for example, to inhibit or reduce growth of P. aeruginosa and/or to prevent or treat P. aeruginosa biofilm infection as well as diseases or disorders associated with P. aeruginosa biofilm infection. The present invention also concerns methods of producing the fusion molecules described herein as well as compositions and kits comprising such fusion molecules. The present invention further relates to nucleic acid molecules encoding the fusion molecules described herein.Type: GrantFiled: July 6, 2016Date of Patent: June 11, 2019Assignee: SANOFIInventors: Carsten Corvey, Heike Stump, Jochen Kruip, Christian Lange, Ingo Focken, Dorothea Rat, Thomas Stuedemann, Hans-Falk Rasser, Juergen Schaefer, Bernard Calandra, Astrid Rey, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Publication number: 20180371038Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: ApplicationFiled: August 14, 2018Publication date: December 27, 2018Inventors: Carsten Corvey, Heike Stump, Jochen Kruip, Bernhard Calandra, Astrid Rey, Nathalie Karst, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Publication number: 20180371037Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: ApplicationFiled: August 14, 2018Publication date: December 27, 2018Inventors: Carsten CORVEY, Heike STUMP, Jochen KRUIP, Bernhard CALANDRA, Astrid REY, Nathalie KARST, Michael MOUREZ, Laurent FRAISSE, Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Marlon HINNER, Bradley LUNDE, Kristian JENSEN, Martin HÜLSMEYER
-
Publication number: 20180346532Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: ApplicationFiled: August 14, 2018Publication date: December 6, 2018Inventors: Carsten CORVEY, Heike STUMP, Jochen KRUIP, Bernhard CALANDRA, Astrid REY, Nathalie KARST, Michael MOUREZ, Laurent FRAISSE, Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Marlon HINNER, Bradley LUNDE, Kristian JENSEN, Martin HÜLSMEYER
-
Patent number: 10118952Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: GrantFiled: October 6, 2017Date of Patent: November 6, 2018Assignee: SANOFIInventors: Carsten Corvey, Heike Stump, Jochen Kruip, Bernhard Calandra, Astrid Rey, Nathalie Karst, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Patent number: 10072056Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: GrantFiled: October 5, 2017Date of Patent: September 11, 2018Assignee: SANOFIInventors: Carsten Corvey, Heike Stump, Jochen Kruip, Bernhard Calandra, Astrid Rey, Nathalie Karst, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Patent number: 10065998Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: GrantFiled: October 6, 2017Date of Patent: September 4, 2018Assignee: SANOFIInventors: Carsten Corvey, Heike Stump, Jochen Kruip, Bernhard Calandra, Astrid Rey, Nathalie Karst, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Publication number: 20180086799Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: ApplicationFiled: November 16, 2017Publication date: March 29, 2018Inventors: Carsten CORVEY, Heike STUMP, Jochen KRUIP, Bernhard CALANDRA, Astrid REY, Nathalie KARST, Michael MOUREZ, Laurent FRAISSE, Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Marlon HINNER, Bradley LUNDE, Kristian JENSEN, Martin HÜLSMEYER
-
Publication number: 20180037619Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: ApplicationFiled: October 6, 2017Publication date: February 8, 2018Inventors: Carsten CORVEY, Heike STUMP, Jochen KRUIP, Bernhard CALANDRA, Astrid REY, Nathalie KARST, Michael MOUREZ, Laurent FRAISSE, Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Marlon HINNER, Bradley LUNDE, Kristian JENSEN, Martin HÜLSMEYER
-
Publication number: 20180037618Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. acruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: ApplicationFiled: October 5, 2017Publication date: February 8, 2018Inventors: Carsten CORVEY, Heike STUMP, Jochen KRUIP, Bernhard CALANDRA, Astrid REY, Nathalie KARST, Michael MOUREZ, Laurent FRAISSE, Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Marlon HINNER, Bradley LUNDE, Kristian JENSEN, Martin HÜLSMEYER
-
Patent number: 9884898Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: GrantFiled: May 23, 2017Date of Patent: February 6, 2018Assignee: SANOFIInventors: Carsten Corvey, Heike Stump, Jochen Kruip, Bernhard Calandra, Astrid Rey, Nathalie Karst, Michael Mourez, Laurent Fraisse, Christine Rothe, Andrea Allersdorfer, Alexander Wiedenmann, Marlon Hinner, Bradley Lunde, Kristian Jensen, Martin Hülsmeyer
-
Publication number: 20180030101Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: ApplicationFiled: October 6, 2017Publication date: February 1, 2018Inventors: Carsten CORVEY, Heike STUMP, Jochen KRUIP, Bernhard CALANDRA, Astrid REY, Nathalie KARST, Michael MOUREZ, Laurent FRAISSE, Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Marlon HINNER, Bradley LUNDE, Kristian JENSEN, Martin HÜLSMEYER
-
Publication number: 20170267734Abstract: The present disclosure provides hNGAL muteins that bind a pyoverdine family member or pyochelin and can be used in various application including pharmaceutical applications, for example, to inhibit or reduce growth of P. aeruginosa. The present disclosure also concerns methods of making one or more pyoverdine- or pyochelin-binding muteins described herein as well as compositions comprising one or more of such muteins. The present disclosure further relates to nucleic acid molecules encoding such muteins and to methods for generation of such muteins and nucleic acid molecules. In addition, the application discloses therapeutic and/or diagnostic uses of these muteins as well as compositions comprising one or more of such muteins.Type: ApplicationFiled: May 23, 2017Publication date: September 21, 2017Inventors: Carsten CORVEY, Heike STUMP, Jochen KRUIP, Bernhard CALANDRA, Astrid REY, Nathalie KARST, Michael MOUREZ, Laurent FRAISSE, Christine ROTHE, Andrea ALLERSDORFER, Alexander WIEDENMANN, Marlon HINNER, Bradley LUNDE, Kristian JENSEN, Martin HÜLSMEYER